Canada to receive 249,000 doses of Pfizer COVID-19 vaccine by the end of December

Canada to receive 249,000 doses of Pfizer COVID-19 vaccine by the end of December

The Government of Canada will receive 249 thousand doses of COVID-19 coronavirus vaccine from Pfizer’s development companies by the end of December 2020. Anita Anand, Minister of Public Services and Purchasing of Canada, told the government’s press office on December 7.

According to her, this supply is among 76 million doses under the current agreement between Canada and Pfizer.

“Like all candidate vaccines from COVID-19, Pfizer vaccine must be approved by the Ministry of Health of Canada before it can be administered to citizens,” the report said.

Canada is completing work this week to meet the priority needs for the vaccine. In particular, training is being provided on transportation and storage of the drug, which requires a temperature of -70 ° C. Also planned is “major logistics research” – delivery of vaccines from the manufacturer to places of use in Canada, the report says.

“These studies are important to ensure that provinces and regions have the infrastructure and equipment they need to effectively deliver COVID-19 vaccines when approved,” the Canadian government added.

“Any vaccine approved in Canada will be safe and effective. Our specialists will adhere to the internationally recognized ‘gold standard’ for medical approvals,” Canadian Prime Minister Justin Trudeau commented on the news.

Pfizer announced on November 18th that 95% of the effectiveness of the COVID-19 BNT162b2 vaccine, developed in conjunction with the German BioNTech, has been achieved. The companies expect to produce up to 50 million doses of the vaccine in 2020 and 1.3 billion by the end of 2021. Pfizer has already sold about 82 percent of its vaccine doses.

World Health Organization head Tedros Adhan Gebrejesus called the Pfizer vaccine “very promising.

According to the World Health Organization, as of December 2, 51 producers of COVID-19 vaccine are candidates for clinical evaluation of the vaccine produced. Preclinical trials are conducted by 163 companies. Preliminary results of the vaccine trials by American Pfizer, developed together with German BioNTech, showed more than 95% efficiency in the third phase of clinical trials.

The outbreak of coronavirus infection began in late 2019 in China. On March 11, 2020, the World Health Organization declared the spread of coronavirus a pandemic.

According to the American Johns Hopkins University, as of December 7, more than 67.4 million people worldwide were infected with COVID-19. 1.54 million people died from this disease and 43.2 million people recovered. 422.8 thousand people in Canada became ill, 12.7 thousand died and 339.9 thousand recovered from the beginning of the pandemic.